Professional Documents
Culture Documents
About Fujirebio
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing.
Fujirebio (the name is pronounced Fuji-Ray-Bee-o and symbolizes restoration of health) has more than 50 years’
experience in the discovery, development, manufacturing and worldwide commercialization of robust IVD products.
Historically based in Japan with the country’s deeply rooted culture of excellence Fujirebio has over the years been
shaped by the successful integration of pioneering and experienced international IVD players such as the diagnostics
business of Centocor in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global pres-
ence includes offices in the United States, Europe, Latin America and Asia as well as a vast international distribution
network.
Fujirebio IVD product lines span from specialized manual testing to fully automated routine clinical laboratory testing
solutions and include both novel and routine biomarkers. They cover a variety of disease states such as infectious,
oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism.
As early pioneers back in 1992 Fujirebio launched one the World’s first fully automated chemiluminescent enzyme
immunoassay systems, the early LUMIPULSE® in Japan. Today Fujirebio is the 2nd largest immunoassay instrument
supplier on the Japanese market. The latest generation of the LUMIPULSE series of chemiluminescent assays and
analyzers was brought to new markets in Asia and Europe in 2011 and, in 2016, to the United States.
Fujirebio also has a strong and long lasting tradition for developing high quality routine and truly novel biomarkers
in collaboration with the clinical community worldwide.
Established in 1950 Fujirebio is today a fully owned subsidiary of Miraca Holdings (listed in the Tokyo Stock Exchange
- MRCHF) and employ more than 1.200 people in Asia, Europe and America, including subsidiaries.
• Tumor markers
- Complete routine oncology panel with gold • Neurodegeneration
standard antibodies: AFP, CEA, CA125, CA19-9, - β-Amyloid 1-42
CA15-3, PSA and fPSA, β2m(serum/urine) - β-Amyloid 1-40*
- Specialized state of the art products: PIVKA-II, CYFRA, - Total Tau
HE4, Pepsinogen I & II, ProGRP and Mesothelin - pTau 181*
p. 3
Tumor markers
CA125II
• Lumipulse® G CA125II Immunoreaction Cartridges 3 × 14 Tests 292631
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
CA125 in serum or plasma.
CA15-3
• Lumipulse® G CA15-3 Immunoreaction Cartridges 3 × 14 Tests 292648
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
CA15-3 in serum or plasma.
CA19-9
• Lumipulse® G CA19-9-N Immunoreaction Cartridges 3 × 14 Tests 292655
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
CA19-9 in serum or plasma.
p. 4
Cytokeratin subunit 19 fragment (CYFRA) description ART. NO.
HE4
• Lumipulse® G HE4 Immunoreaction Cartridges 3 × 14 Tests 234068
For in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
HE4 in serum and plasma.
p. 5
Pepsinogen I and II description art. no.
Mesothelin (SMRP)
• Lumipulse® G Mesothelin Immunoreaction Cartridges 3 x 14 Tests 294192
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
Mesothelin (SMRP) in serum or plasma.
Thyroid
p. 6
Free thyroxine (FT4) description art. no.
Thyroxine (T4)
• Lumipulse® G T4 Immunoreaction Cartridges 3 × 14 Tests 294451
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
thyroxine (T4) in serum or plasma.
Triiodothyronine (T3)
• Lumipulse® G T3 Immunoreaction Cartridges 3 × 14 Tests 294413
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
triiodothyronine (T3) in serum or plasma.
p. 7
Neurodegeneration
Total Tau
• Lumipulse® G Total Tau Immunoreaction Cartridges 3 x 14 Tests 230312
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
total Tau in human cerebrospinal fluid.
β-Amyloid 1-40*
• Lumipulse® G β-Amyloid 1-40 Immunoreaction Cartridges 3 × 14 Tests 231524
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
β-Amyloid 1-40 in human cerebrospinal fluid.
pTau 181*
• Lumipulse® G pTau 181 Immunoreaction Cartridges
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of 3 x 14 Tests 230350
pTau in human cerebrospinal fluid.
Cardiac
BNP
• Lumipulse® G BNP Immunoreaction Cartridges 3 x 14 Tests 296899
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
human B-type natriuretic peptide (BNP) in human EDTA plasma.
* in development
p. 8
description art. no.
CK-MB
• Lumipulse® G CK-MB Immunoreaction Cartridges 3 x 14 Tests 298169
For in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
the MB isoenzyme of creatine kinase (CK-MB) in human serum or plasma.
Myoglobin
• Lumipulse® G Myoglobin Immunoreaction Cartridges 3 × 14 Tests 298145
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
myoglobin in human serum or plasma.
hs Troponin I
• Lumipulse® G hs Troponin I Immunoreaction Cartridges 3 x 14 Tests 298121
For in vitro diagnostic use with the LUMIPULSE® G System for the quantitative and high sensitive
measurement of cardiac troponin I in serum or plasma.
Fertility
Beta Human Chorionic Gonadotropin (βHCG)
• Lumipulse® G ßHCG Immunoreaction Cartridges 3 × 14 Tests 295151
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
total beta human chorionic gonadotropin (βHCG) in serum or plasma.
p. 9
Luteinizing hormone (LH) description art. no.
Prolactin (PRL)
• Lumipulse® G Prolactin Immunoreaction Cartridges 3 × 14 Tests 292839
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
prolactin in serum or plasma.
Testosterone
• Lumipulse® G Testosterone Immunoreaction Cartridges 3 × 14 Tests 292952
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
testosterone in serum or plasma.
Estradiol (E2)
• Lumipulse® G E2-III Immunoreaction Cartridges 3 × 14 Tests 296011
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
estradiol (E2) in serum or plasma.
Progesterone (PRG)
• Lumipulse® G Progesterone-N Immunoreaction Cartridges 3 x 14 Tests 295564
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
progesterone (PRG) in serum or plasma.
* in development
p. 10
Diabetes & Inflammation
Insulin
• Lumipulse® G Insulin-N Immunoreaction Cartridges 3 × 14 Tests 292938
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
insulin in serum or plasma.
HMW Adiponectin
• Lumipulse® G HMW Adiponectin Immunoreaction Cartridges 3 x 14 Tests 234778
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
High Molecular Weight (HMW) Adiponectin in serum or plasma.
Immunoglobulin E (IgE)
• Lumipulse® G IgE Immunoreaction Cartridges 3 × 14 Tests 292815
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
immunoglobulin E (IgE) in serum or plasma.
Procalcitonin (PCT)
• Lumipulse® G B. R. A. H. M. S PCT Immunoreaction Cartridges 3 x 14 Tests 297902
For in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
Procalcitonin in serum or plasma.
Interleukin (IL-6)**
• IL-6 LPG Immunoreaction Cartridges RUO 3 x x14 Tests 293423
For in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
IL-6 in serum or plasma.
p. 11
Infectious diseases
Hepatitis B virus
• Lumipulse® G HBsAg-Quant Immunoreaction Cartridges 3 x 14 Tests 296851
For in vitro diagnostic use with the LUMIPULSE® G System for the qualitative and quantitative
detection of hepatitis B surface antigen (HBsAg) in human serum or plasma.
• Lumipulse® G HBsAg-Quant Calibrators 1 × 6 x 2 ml 233139
HTLV I/II
• Lumipulse® G HTLV-I/II Immunoreaction Cartridges set*** 3 x 14 Tests 234617
For in vitro diagnostic use with the LUMIPULSE® G System for the qualitative detection of 1 x 2 x 1.5ml
antibody to human T-cell lymphotropic virus type I (HTLV- I) and type II (HTLV- II) in human
serum or plasma.
p. 12
Bone
25-OH Vitamin D description art. no.
Whole-Parathyroid Hormone (whole PTH)
• Lumipulse® G whole PTH Immunoreaction Cartridges 3 × 14 Tests 297094
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
whole (1-84) PTH in human serum or plasma.
Anemia
Ferritin
• Lumipulse® G Ferritin-N Immunoreaction Cartridges 3 × 14 Tests 292969
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
ferritin in serum or plasma.
Interstitial pneumonia
Krebs von den Lungen (KL-6)
• Lumipulse® G KL-6 Immunoreaction Cartridges 3 × 14 Tests 233207
F or in vitro diagnostic use with the LUMIPULSE® G System for the quantitative measurement of
sialylated carbohydrate antigen, KL-6 in serum or plasma.
p. 13
Consumables
Common reagents
p. 14
Instrumentation
p. 15
art. no.
• LUMIPULSE® G600II
Simplify your work using LUMIPULSE G600II as a personalized solution. The benchtop CLEIA analyzer 703380
processes mono-test cartridges at a rate of 60 tests/hour, a consistent throughput regardless of assay mix .
p. 16
Controls
art. no.
• Lumipulse® PIVKA-II and KL-6 Controls
For in vitro diagnostic use: This control is intended for use as an assayed control serum to monitor the precision
233801
of laboratory testing procedures for the analysis of PIVKA-II and KL-6 using LUMIPULSE® G Systems.
Level 1: 3 x 1ml Level 2: 3 x 1ml
• Vitamin D Control
Fujirebio Vitamin D Control is intended for use as an assayed control serum to monitor the precision 2130152
of laboratory testing procedures for the analysis of Vitamin D. This control contains both 25(OH) Vitamin D2 and
25(OH) Vitamin D3; and when combined represent clinically relevant levels of Total Vitamin D.
Level 1: 2 x 2ml Level 2: 2 x 2ml Level 3: 2 x 2 ml
• ProGRP Control
For in vitro diagnostic use: This control is intended for use as an assayed control serum to monitor the precision 230-20
of laboratory testing procedures for the analysis of ProGRP using LUMIPULSE® G Systems.
Level 1: 3 x 1ml Level 2: 3 x 1ml
* In development
Assigned values for controls are available. For more info on these and on external quality controls, contact your local representative.
p. 17
Controls
art. no.
• Lumipulse® B. R. A. H. M. S PCT Controls 234167
For in vitro diagnostic use: These controls are intended for use as an assayed control material to monitor the
precision of laboratory testing procedures for the analysis of procalcitonin on the LUMIPULSE® G Systems.
Level 1: 6 x 1 ml Level 2: 6 x 1 ml
* Coming soon
p. 18
2016
The LUMIPULSE®
G1200, a mid-sized,
cartridge-based
instrument for fully
2015 automated CLEIA
The LUMIPULSE® testing, is launched
L2400, a high in the USA.
volume instrument
using bottle-type
reagents is launched 2014
in Japan. The LUMIPULSE®
G600II, a compact
cartridge-based
CLEIA benchtop
2011 analyzer, is launched
The LUMIPULSE® in Europe and Asia.
G1200, a mid-sized,
cartridge-based
instrument for fully
automated CLEIA
testing, is launched
2010
When you
in Europe and Asia. Acquisition of
Innogenetics NV
(Belgium), world
you have to
Cross choose LUMI-
PULSE® as their
blood screening
system. 2006
Acquisition of CanAg
Diagnostics AB
(Sweden), leader in carve every step
with care
oncology biomarker
2005 development.
Fujirebio Inc. be-
comes a fully owned
subsidiary of
Miraca Holdings Inc.
2001
Fujirebio is accredit-
ed with
ISO 13485, ISO 9001,
EN46001 and
1998 ISO 14001 certifica-
Acquisition of Cen- tions.
tocor Diagnostics
(USA), pioneer in
oncology testing and
developer of CA125II,
CA19-9 and CA15-3.
1995
The INNOTEST®
hTAU Ag kit is the
world’s first com-
mercialised
1992 biomarker for early
detection of Alzhei-
Fujirebio launches
mer’s Disease.
the original
LUMIPULSE® 1200
instrument in Japan.
Launch of the first 1987
specialised infectious Fujirebio Inc. is
disease tests on the listed on the TSE
INNO-LiPA®, INNO-LIA® (Tokyo Stock Exchange)
and INNOTEST® plat- – 1st section.
forms.
1985
Launch of Immuno-
clone CA19-9, the first
1978
carbohydrate oncolo- Launch of the
gy assay. syphilis SERO-
DIA®-TP•PA test kit,
destined to become
1966 the gold standard.
Launch of HA Ag
(TPHA), the first
hemagglutination
test for syphilis.
1950
Fujirebio (formerly
Fujizoki Pharmaceutical,
Co., Inc.) is founded in
Tokyo, Japan.
p. 19
© Fujirebio Europe, March 2018, FRE-033, r2
Fujirebio Europe Corporate Office: Sales Assistance:
Fujirebio Europe NV Tel.: +32-9-329-1417
Technologiepark 6 Fax: +32-9-329-1775
B-9052 Gent e-mail: info@fujirebio.com
BELGIUM
BTW BE 0427.550.660 - Companies Register Gent
Tel.: +32-9-329-1329 Order Handling:
Fax: +32-9-329-1911 Tel.: +32-9-329-1516 - +32-9-329-1527
e-mail: info@fujirebio-europe.com Fax: +32-9-245-7613
website: www.fujirebio.com e-mail: orderhandling@fujirebio.com
Customer Support:
Tel.: +32-9-329-1611
Fax: +32-9-329-1911
e-mail: customer.support@fujirebio.com